In the present study, we aimed to retrospectively examine the efficacy and safety of therapeutic regimen simplification using iGlarLixi or IDegLira over a 24-month observation period using real-world data, including patients with high total daily insulin dose (TDD, > 60 U/day), high initial HbA1c (> 8.0%), and long diabetes duration. Here, INS is linked to diabetes mellitus.